Sage Therapeutics and Biogen Announce the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints | Newsroom - UNC Health and UNC School of Medicine

Submitted by Anonymous (not verified) on Thu, 06/02/2022 - 14:19

Sage Therapeutics and Biogen Announce the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints | Newsroom  UNC Health and UNC School of Medicine